中国P站

Renal atherosclerosis, characterized by the narrowing and hardening of the arteries supplying the kidneys, is a significant contributor to chronic kidney disease (CKD) and end-stage renal disease (ESRD), as well as an important factor in the development and progression of systemic hypertension and cardiovascular events. Unlike atherosclerosis in other vascular beds, renal artery stenosis (RAS) often presents with unique pathological features and clinical consequences due to the kidney’s intricate vascular architecture and its crucial role in blood pressure regulation and waste filtration. The progression of renal atherosclerosis is a complex and multifaceted process involving endothelial dysfunction, lipid deposition, inflammatory cell infiltration, smooth muscle cell proliferation, and extracellular matrix remodeling within the renal arterial walls. Understanding the detailed pathological mechanisms underlying this progression is crucial for developing effective diagnostic and therapeutic strategies to prevent or slow the decline in renal function and mitigate associated cardiovascular risks. This manuscript aims to provide a comprehensive overview of the pathological insights into the progression of renal atherosclerosis, detailing the key cellular and molecular events that contribute to the development and advancement of this condition, ultimately leading to renal parenchymal damage and functional impairment [1].

Description

The initiation of renal atherosclerosis, similar to atherosclerosis in other vascular beds, begins with endothelial dysfunction. The endothelium, the inner lining of the renal arteries, plays a critical role in maintaining vascular tone, inhibiting platelet aggregation, and preventing leukocyte adhesion. Various risk factors, including hypertension, diabetes mellitus, hyperlipidemia, and smoking, can damage the endothelium, leading to increased permeability and the expression of adhesion molecules. This allows for the infiltration of monocytes and low-density lipoproteins (LDL) into the subendothelial space. Once in the intima, monocytes differentiate into macrophages, which avidly engulf oxidized LDL (ox-LDL), transforming into foam cells, the hallmark of early atherosclerotic lesions, also known as fatty streaks [2]. The accumulation of foam cells triggers an inflammatory response, characterized by the release of pro-inflammatory cytokines and chemokines, such as tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), ¹ and monocyte chemoattractant protein-1 (MCP-1), which further recruit more inflammatory cells and perpetuate the cycle of inflammation and lipid accumulation. As the atherosclerotic lesion progresses, smooth muscle cells (SMCs) from the media migrate into the intima and undergo proliferation. These SMCs contribute to the formation of the fibrous cap, a protective layer that covers the lipid-rich core of the plaque. They also synthesize extracellular matrix components, such as collagen and elastin, which contribute to the thickening and hardening of the arterial wall. In renal arteries, the unique hemodynamic environment, characterized by pulsatile flow and relatively low pressure compared to the aorta, may influence the specific patterns of plaque development and progression. Branch points and ostial regions of the renal arteries are particularly susceptible to atherosclerotic lesions due to disturbed flow patterns that promote endothelial dysfunction. The progression of renal atherosclerotic plaques can lead to luminal narrowing (renal artery stenosis), which reduces blood flow to the affected kidney [3]. This ischemia triggers the activation of the renin-angiotensin-aldosterone system (RAAS), leading to the release of renin and subsequent increases in angiotensin II and aldosterone. Angiotensin II is a potent vasoconstrictor that further elevates systemic blood pressure and can directly contribute to endothelial dysfunction and inflammation within the renal vasculature. Aldosterone promotes sodium and water retention, also contributing to hypertension and potentially exacerbating renal damage [4].

Chronic ischemia can lead to parenchymal atrophy, characterized by tubular damage, interstitial fibrosis, and glomerular sclerosis, ultimately resulting in a decline in glomerular filtration rate and the progression of CKD. Furthermore, renal atherosclerotic plaques can undergo complex changes, including plaque rupture or erosion, leading to thrombus formation and acute kidney injury or renovascular hypertension. The composition of the atherosclerotic plaque, including the presence of a large lipid-rich core, thin fibrous cap, and inflammatory cell infiltration, influences its vulnerability to rupture [5].

Calcification within the plaque, while often considered a marker of advanced disease, can also contribute to arterial stiffness and impaired vascular reactivity. The interaction between systemic atherosclerosis and renal atherosclerosis is also significant. Patients with renal artery stenosis often have coexisting atherosclerotic disease in other vascular beds, increasing their risk of cardiovascular events such as myocardial infarction and stroke [6].

The inflammatory milieu associated with systemic atherosclerosis can also contribute to the progression of renal vascular disease. Understanding the intricate interplay of these pathological processes, from the initial endothelial injury to the advanced stages of plaque development, luminal stenosis, and subsequent renal parenchymal damage, is crucial for developing targeted therapies aimed at preventing or slowing the progression of renal atherosclerosis and its devastating consequences [7,8].

Conclusion

The progression of renal atherosclerosis is a complex and dynamic process driven by a cascade of cellular and molecular events, starting with endothelial dysfunction and culminating in significant luminal stenosis, renal ischemia, and parenchymal damage. The interplay of lipid accumulation, inflammation, smooth muscle cell proliferation, and extracellular matrix remodeling contributes to the formation and progression of atherosclerotic plaques within the renal arteries. The unique hemodynamic environment of the renal vasculature and the activation of the renin-angiotensin-aldosterone system in response to renal ischemia further complicate the pathological landscape. Understanding the detailed mechanisms underlying these processes is essential for developing effective strategies for early diagnosis, risk stratification, and targeted therapeutic interventions. Future research should focus on identifying novel biomarkers for early detection, elucidating the specific roles of different inflammatory mediators and signaling pathways in the progression of renal atherosclerosis, and developing therapies that not only address traditional risk factors but also directly target the pathological processes within the renal arterial wall. Ultimately, a deeper understanding of the pathological insights into the progression of renal atherosclerosis will pave the way for more effective prevention and treatment strategies aimed at preserving renal function, controlling hypertension, and reducing the cardiovascular burden associated with this increasingly prevalent condition.

Acknowledgement

None

Conflict of Interest

None

References

1. Becker LM, Chen SH, Rodor J, de Rooij LP, Baker AH, et al. (2022) Cardiovasc Res 119: 6-27.

   , ,

2. Grootaert MO, Bennett MR (2021) Cardiovasc Res 117: 2326-2339.

   , ,

3. Fernandez DM, Rahman AH, Fernandez NF, Chudnovskiy A, Amir EAD, et al. (2019) Nat Med 25: 1576-1588.

   , ,

4. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, et al. (2017) N Engl J Med 377: 1119-1131.

   , ,

5. Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, et al. (2019) N Engl J Med 381: 2497-2505.

   , ,

6. Fiolet AT, Cornel JH, Thompson PL (2020) N Engl J Med 383: 1838-1847.

   , ,

7. Raj A, Van OA (2008) Cell 135: 216-226.

   , ,

8. Perisic L, Aldi S, Sun Y, Folkersen L, Razuvaev A, et al. (2016) J Intern Med 279: 293-308.

   , ,